Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers
Status: UNKNOWN
Study type: INTERVENTIONAL
Conditions: Acute Myelogenous Leukemia|Ovarian Cancer|Colorectal Cancer|Triple-negative Breast Cancer|Small-cell Lung Cancer
Interventions: BIOLOGICAL: galinpepimut-S|DRUG: Pembrolizumab
Sponsor: Sellas Life Sciences Group
Collaborators: Merck Sharp & Dohme LLC|Cancer Insight, LLC